Domo signs strategic collaboration agreement with AWS for AI solutions
Krista Davis, Senior Vice President and Chief Human Resources Officer at ANI Pharmaceuticals (NASDAQ:ANIP), executed a sale of 1,866 shares of the company’s common stock on March 19, 2025. The shares were sold at a price of $65 each, resulting in a total transaction value of $121,290. Following this sale, Davis holds 64,659 shares directly. The transaction comes as the $1.31 billion market cap company has shown strong momentum, with shares up 17.35% year-to-date and earning a "GREAT" financial health score from InvestingPro.
This transaction was conducted under a Rule 10b5-1 trading plan, which was adopted by Davis in August 2024. Such plans allow insiders to set up a predetermined schedule for selling stocks, providing a defense against potential accusations of insider trading. Looking ahead, five analysts have revised their earnings estimates upward, and InvestingPro analysis reveals 8 additional key insights about ANI Pharmaceuticals’ financial outlook and valuation.
In other recent news, ANI Pharmaceuticals has launched its Nitazoxanide Tablets, a generic version of Alinia®, with U.S. annual sales estimated at approximately $36.1 million. The company also completed a $17.25 million buyout of its royalty obligation to SWK Funding LLC, which will cease royalty payments on ILUVIEN and YUTIQ from January 2025. Additionally, the FDA has approved an updated label for ILUVIEN, expanding its use to treat chronic non-infectious uveitis affecting the posterior segment of the eye. This update includes changes to the Warnings and Precautions section, enhancing patient safety information. Jefferies initiated coverage on ANI Pharmaceuticals with a Buy rating and a price target of $80, citing the company’s promising Cortrophin Gel and generic drug offerings. JPMorgan also began coverage with an Overweight rating and set a price target of $85, highlighting the growth potential in ANI’s branded and generic product portfolio. The firm’s analysts see particular promise in the company’s lead product, Cortrophin Gel, and its recent acquisitions, YUTIQ and ILUVIEN. These developments collectively reflect ANI Pharmaceuticals’ strategic moves to enhance its market position and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.